On November 25, 2025, the Board of Directors of Tyra Biosciences, Inc. appointed Bhavesh Ashar as the Company?s Chief Operating Officer, succeeding Daniel Bensen in that position, who was appointed the Company?s Chief Discovery Officer, each effective as of December 1, 2025. Mr. Ashar, 60, brings more than 25 years of global pharmaceutical and biotechnology experience. He most recently served as Chief Commercial Officer of SpringWorks Therapeutics, Inc. from March 2021 through its acquisition by Merck KGaA in July 2025, where he built the commercial infrastructure and successfully launched two U.S. rare oncology products?OGSIVEO® (nirogacestat) and GOMEKLI (mirdametinib)?and advanced readiness for European launches.
From May 2017 to March 2021, Mr. Ashar served as Senior Vice President, General Manager of U.S. Oncology at Bayer, overseeing a broad portfolio in prostate, liver, colorectal, gastrointestinal stromal tumor, hematologic, and tumor-agnostic biomarker-driven cancers. Before Bayer, he spent approximately 15 years at Sanofi Genzyme in roles of increasing responsibility, including Vice President, General Manager of U.S. Oncology and Vice President, Global Head of Transplant (Oncology Division). Earlier in his career, he was a consultant with McKinsey & Company, serving biopharmaceutical clients.
Mr. Ashar holds a Bachelor of Science in Mathematics from Imperial College London and an MBA from the University of Chicago Booth School of Business.
